SCHEMBL23746478

SCHEMBL23746478

Bc1c(B)c(B)c(-c2cc(C(=O)NCC3CNC3)c3ccccc3n2)c(B)c1B

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACB O00763 9/20 0.52
MEN1 O00255 1/20 0.51
CACNA1B Q00975 1/20 0.51
APBA1 Q02410 1/20 0.51
KMT2A Q03164 1/20 0.51
ALDH1A1 P00352 6/20 0.50
KDM4E B2RXH2 5/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
TACR3 P29371 1/20 0.49
ACACA Q13085 7/20 0.49
GAA P10253 3/20 0.46
GLA P06280 1/20 0.46
POLB P06746 1/20 0.46
MAPT P10636 1/20 0.46
HPGD P15428 1/20 0.46
ESR2 Q92731 1/20 0.46
HSD17B10 Q99714 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
CYP3A4 P08684 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23722853 0.86 ACACB (0.66) ACACBMEN1CACNA1BAPBA1KMT2A
SCHEMBL23722823 0.82 GAA (0.58) ACACBMEN1KMT2AALDH1A1KDM4E
SCHEMBL23722822 0.81 KDM4E (0.69) MEN1CACNA1BAPBA1KMT2AALDH1A1
SCHEMBL23722914 0.81 KDM4E (0.67) MEN1KMT2AALDH1A1KDM4ETACR3
SCHEMBL23746703 0.80 CACNA1B (0.62) MEN1CACNA1BAPBA1KMT2AALDH1A1
SCHEMBL23746673 0.79 MEN1 (0.60) MEN1CACNA1BAPBA1KMT2AALDH1A1
SCHEMBL23746698 0.78 KDM4E (0.63) ACACBALDH1A1KDM4EL3MBTL1TACR3
SCHEMBL23746385 0.77 MOK (0.65) MEN1CACNA1BAPBA1KMT2AALDH1A1
SCHEMBL4391974 0.76 ACACB (0.74) ACACBALDH1A1KDM4EL3MBTL1TACR3
SCHEMBL4391971 0.76 ACACB (0.74) ACACBALDH1A1KDM4EL3MBTL1TACR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210244721-A1 SMALL MOLECULE ENTEROVIRUS INHIBITORS AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2021-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210244721-A1 SMALL MOLECULE ENTEROVIRUS INHIBITORS AND USES THEREOF AR, KLK3, BRDT ACACB 3935/4885MEN1 56/4885CACNA1B 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.